AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2026
Jan 5, 2026
32883_dirs_2026-01-05_4f17b5c8-fa59-41b1-8840-f04803fc40a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2026-01-01
Reporting Person: RIOUX PATRICE (Acting Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-01 | Stock Option | $65.30 | A | 2000 | Acquired | 2036-01-01 | Common Stock (2000) | Direct |
Footnotes
F1: Stock Options vesting commenced on January 1, 2026 as follows: 1/12th of the 2,000 options vest on January 31, 2026 and each subsequent month-end thereafter.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2